News Sentiment

CSBR sentiment intelligence

Champions Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.13 Week of 17 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.3% over one week, -3.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Champions Oncology to announce Q4 and FY26 results on July 27

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 5.3% Price confirming higher
Trend fit Trend inactive -3.0% over four weeks
Fair value -2.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 30
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 13
TradingKey 9
Market source 6
dars.gov.et 3
Stock Traders Daily 2
simplywall.st 2
scanx.trade 1
Hastings Tribune 1

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 20
Guidance 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
scanx.trade Direct company coverage

Champions Oncology to announce Q4 and FY26 results on July 27

Champions Oncology, Inc. will release its financial and operational results for the quarter and fiscal year ended April 30, 2026, after market close on Monday, July 27, 2026. The company will also host a conference call on the same day at 4:30 P.M. ET to discuss these results. Re

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 05:40
Source
scanx.trade
Stock Titan Direct company coverage

Champions Oncology Schedules Year-End Results Call for 4:30 p.m.

Champions Oncology (NASDAQ: CSBR) announced it will report its financial and operational results for the fourth quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call on the same day at 4:30 P.M. ET to discuss

Tone
Positive 65/100
Event
Earnings
Published
20 Jul 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3

This article from TradingView provides financial information for Champions Oncology, Inc. (SWB:2I3), specifically focusing on its enterprise value to EBITDA forward. It indicates that the company is listed on the Stuttgart Stock Exchange and presents various financial metrics and

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 06:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Champions Oncology, Inc. – DUS:2I3

The article focuses on the "Enterprise value to EBITDA forward" metric for Champions Oncology, Inc. (DUS:2I3) listed on the Dusseldorf Stock Exchange. It appears to be a financial data point provided by TradingView, without presenting any specific values or detailed financial ana

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:16
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Champions Oncology, Inc. – DUS:2I3

This article focuses on the enterprise value to EBIT forward for Champions Oncology, Inc. (DUS:2I3) as listed on the Dusseldorf Stock Exchange. It appears to be a financial data point from a trading platform, indicating market closed with no trades. The content primarily lists va

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 22:10
Source
TradingView
Stock Traders Daily Direct company coverage

Trading the Move, Not the Narrative: (CSBR) Edition

This article analyzes Champions Oncology Inc. (NASDAQ: CSBR), highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies—Position

Tone
Negative 36/100
Event
Market update
Published
13 Jul 2026 18:46
Source
Stock Traders Daily
TradingView Direct company coverage

CSBR Q4'25 Earnings: revenue estimate is 12.89M USD

Champions Oncology, Inc. (CSBR) is scheduled to release its Q4'25 earnings on July 16, with an estimated revenue of $12.89 million and an anticipated EPS of ($0.05). The article provides a detailed table of past and estimated revenue and EPS figures, highlighting previous surpris

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 11:12
Source
TradingView
Stock Traders Daily Direct company coverage

(CSBR) Volatility Zones as Tactical Triggers

Champions Oncology Inc. (NASDAQ: CSBR) is currently showing near-term weak sentiment, challenging mid-term strength within a broader long-term weak bias, according to an AI analysis. The article outlines three distinct trading strategies—Position Trading, Momentum Breakout, and R

Tone
Negative 36/100
Event
Market update
Published
02 Jul 2026 17:38
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to revenue forward of Champions Oncology, Inc. – NASDAQ:CSBR

This article provides the enterprise value to revenue forward for Champions Oncology, Inc. (NASDAQ:CSBR). It appears to be a financial data point presented on the TradingView platform, with information on market data providers and copyright notices. The content primarily consists

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 23:09
Source
TradingView
The AI Journal Direct company coverage

Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight

The global oncology-based in-vivo CRO market is projected to reach USD 3.2 billion by 2034, growing at a CAGR of approximately 8%, driven by the rising cancer burden, increasing R&D outsourcing, and advancements in animal models. North America currently leads the market, but the

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:09
Source
The AI Journal
TradingView Direct company coverage

Price to sales forward of Champions Oncology, Inc. – NASDAQ:CSBR

This article provides financial information for Champions Oncology, Inc. (NASDAQ: CSBR), specifically focusing on its price-to-sales forward ratio. It indicates that the market was closed at the time of publication, with no trades reported. The content is primarily a data placeho

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Champions Oncology, Inc. – FWB:2I3

This article provides financial information for Champions Oncology, Inc. (FWB:2I3) listed on the Frankfurt Stock Exchange, specifically focusing on its price-to-book forward ratio. It seems to be an excerpt from a financial data platform, indicating the period, value, and change

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Champions Oncology, Inc. – NASDAQ:CSBR

The article focuses on the "Price to earnings forward" metric for Champions Oncology, Inc. (NASDAQ: CSBR). It provides a brief overview of the company's financial data on the TradingView platform, indicating that the market is currently closed with no trades. The content highligh

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Champions Oncology, Inc. – FWB:2I3

This article provides financial information for Champions Oncology, Inc. (FWB:2I3) regarding its Price to Earnings forward. The data is available on the TradingView platform, which sources market and reference data from ICE Data Services and FactSet, respectively. The article emp

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Champions Oncology, Inc. – FWB:2I3

This article displays the enterprise value to EBITDA forward for Champions Oncology, Inc. (FWB:2I3) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades recorded for this specific financial metric. The content primarily focuses on the f

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR)

This article provides an overview of Champions Oncology, Inc. (NASDAQ: CSBR) stock, including its current price, market capitalization, and historical performance. It also details financial estimates and actuals, highlighting revenue, earnings per share, and upcoming earnings rep

Tone
Negative 39/100
Event
Earnings
Published
25 Jun 2026 18:11
Source
TradingView
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk

Champions Oncology Inc (CSBR) has a risk assessment score of 3.34, placing it 138th out of 387 in the Biotechnology & Medical Research industry. The company's beta of 0.40 indicates lower volatility compared to the S&P 500. The report details various risk metrics including maximu

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis

Champions Oncology Inc (CSBR) currently holds a financial score of 8.65, placing it 37th out of 387 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% ye

Tone
Negative 29/100
Event
Earnings
Published
21 Jun 2026 09:11
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Champions Oncology Inc (CSBR), highlighting its current valuation score of 8.91 within the Biotechnology & Medical Research industry. It notes that the company's P/E ratio is -36.64, which is significantly below its recent high and ab

Tone
Negative 41/100
Event
Market update
Published
19 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Champions Oncology Inc (CSBR), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, CSBR had a price momentum score of 7.27, trading between re

Tone
Positive 61/100
Event
Market update
Published
19 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Institutional Confidence

Champions Oncology Inc (CSBR) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 47.97%, marking a 7.89% decrease quarter-over-quarter. James Simons is the lar

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:10
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Champions Oncology Inc (CSBR) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.15. Analysts have set a price target of $12.00 for CSBR. The company's expected revenue for the next quarter is $12.89 million, and its EPS fo

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:10
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Champions Oncology Inc (CSBR). It notes that the company has distributed $0.00 in dividends over the past five years and shows no recorded data for past stock splits. The article also includes current stock p

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Champions Oncology Inc (CSBR), outlining its major shareholders and institutional holdings. It provides a breakdown of individual and corporate shareholders, their proportions, and a historical view of institutional shareholding o

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Champions Oncology Inc (CSBR), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for FY2026Q3, FY2026Q2, FY2026Q1, and FY2025Q3 have not yet been disclosed by the company, but does s

Tone
Negative 28/100
Event
Earnings
Published
17 Jun 2026 10:39
Source
TradingKey
Intellectia AI Direct company coverage

CSBR Technical Analysis & Stock Price Forecast

This article provides a technical analysis of Champions Oncology Inc (CSBR), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. Key metrics like MACD, RSI, and moving averages suggest bearish momentum, with the stock trading below its

Tone
Negative 30/100
Event
Guidance
Published
03 Jun 2026 06:09
Source
Intellectia AI